RAD51 has been explored as a pharmacological target in two different ways, first, in cancers known to overexpress RAD51, compounds with single-agent activity have been described that exploit overexpression by inducing formation of toxic RAD51 complexes on undamaged DNA. Here, RAD51 is linked to cancer.